SCM
FENC icon

Solas Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

Solas Capital Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.3M Sell
1,889,366
-592,832
-24% -$4.84M 10.88% 1
2026
Q1 		$15.3M Sell
2,482,198
-78,528
-3% -$606K 8.78% 2
2025
Q4 		$19.7M Buy
2,560,726
+372,824
+17% +$3.06M 11.19% 1
2025
Q3 		$20.5M Sell
2,187,902
-45,000
-2% -$390K 12.5% 1
2025
Q2 		$18.5M Sell
2,232,902
-18,017
-0.8% -$123K 10.37% 2
2025
Q1 		$13.7M Hold
2,250,919
– – 7.71% 4
2024
Q4 		$14.2M Buy
2,250,919
+327,383
+17% +$1.68M 9.45% 2
2024
Q3 		$9.62M Buy
1,923,536
+583,536
+44% +$3.38M 6.75% 7
2024
Q2 		$8.19M Buy
1,340,000
+229,767
+21% +$1.91M 4.48% 11
2024
Q1 		$12.3M Sell
1,110,233
-268,280
-19% -$2.69M 7.94% 5
2023
Q4 		$15.5M Sell
1,378,513
-347,054
-20% -$2.88M 9.6% 2
2023
Q3 		$13M Buy
1,725,567
+286,539
+20% +$2.33M 9.07% 3
2023
Q2 		$12.7M Buy
1,439,028
+154,485
+12% +$1.28M 8.45% 2
2023
Q1 		$10.7M Buy
1,284,543
+32,155
+3% +$298K 5.71% 7
2022
Q4 		$12M Buy
1,252,388
+121,221
+11% +$1.07M 7.21% 4
2022
Q3 		$9.16M Sell
1,131,167
-42,349
-4% -$291K 5.59% 5
2022
Q2 		$6.55M Buy
1,173,516
+27,720
+2% +$161K 3.91% 11
2022
Q1 		$6.42M Buy
1,145,796
+277,939
+32% +$1.4M 3.89% 12
2021
Q4 		$3.82M Hold
867,857
– – 2.72% 17
2021
Q3 		$8.18M Hold
867,857
– – 5.69% 5
2021
Q2 		$6.33M Buy
867,857
+67,857
+8% +$453K 4.44% 9
2021
Q1 		$4.97M Hold
800,000
– – 4.18% 9
2020
Q4 		$5.96M Hold
800,000
– – 4.55% 9
2020
Q3 		$4.85M Sell
800,000
-160,000
-17% -$1.13M 4.64% 8
2020
Q2 		$8.02M Hold
960,000
– – 7.4% 3
2020
Q1 		$5.7M Sell
960,000
-11,795
-1% -$76.9K 6.17% 5
2019
Q4 		$6.31M Buy
971,795
+28,595
+3% +$154K 6.06% 6
2019
Q3 		$4.54M Buy
943,200
+93,221
+11% +$411K 4.69% 10
2019
Q2 		$3.4M Buy
+849,979
New +$3.6M 3.47% 12

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM

Solas Capital Management's FENC Position: Q2 2026 in Review

Solas Capital Management reduced its Fennec Pharmaceuticals (FENC) stake by 24% in Q2 2026, selling an estimated $4.84M and leaving 1,889,366 shares worth $20.3M. The position accounts for 10.88% of the portfolio, ranked #1.

Solas Capital Management first reported a position in FENC in Q2 2019 and has held it in 29 quarters since. The position peaked at $20.5M in Q3 2025. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Solas Capital Management held 1,889,366 shares of Fennec Pharmaceuticals worth $20.3M as of Q2 2026.
  • Solas Capital Management sold 592,832 Fennec Pharmaceuticals shares in Q2 2026, an estimated $4.84M.
  • Fennec Pharmaceuticals made up 10.88% of Solas Capital Management's portfolio in Q2 2026, its #1 holding.
  • Solas Capital Management first reported a position in Fennec Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Solas Capital Management's Fennec Pharmaceuticals position peaked at $20.5M in Q3 2025.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Solas Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.